Cas no 106678-69-7 (Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI))
Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI) Chemical and Physical Properties
Names and Identifiers
-
- Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI)
- (GLU2)-TRH
- Epidermal Mitosis Inhibiting Pentapeptide
- Pyr-glu-asp-ser-gly-oh
- CHALONE
- Epidermal inhibitory pentapeptide
- EPIDERMAL PENTAPEPTIDE
- EPP
- L-pGlu-L-Glu-L-Asp-L-Ser-Gly-OH
- L-pGlu-L-Glu-L-Asp-L-Ser-L-Gly-OH
- PYR-GLU-ASP-SER-GLY
- pGlu-Glu-Asp-Ser-Gly
- Glycine, N-(N-(N-(N-(5-oxo-L-prolyl)-L-alpha-glutamyl)-L-alpha-aspartyl)-L-seryl)-
- DTXSID00910074
- pyroGlu-Glu-Asp-Ser-GlyOH
- Pyroglutamyl-glutamyl-aspartyl-seryl-glycine
- 5-{[3-Carboxy-1-({1-[(carboxymethyl)imino]-1,3-dihydroxypropan-2-yl}imino)-1-hydroxypropan-2-yl]imino}-5-hydroxy-4-{[hydroxy(5-hydroxy-3,4-dihydro-2H-pyrrol-2-yl)methylidene]amino}pentanoic acid
- Pglu-glu-asp-ser-glyoh
- 106678-69-7
- Epp peptide
- (4S)-5-[[(2S)-3-carboxy-1-[[(2S)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid
- (3S,6S,9S)-3-(2-carboxyethyl)-6-(carboxymethyl)-9-(hydroxymethyl)-1,4,7,10-tetraoxo-1-((S)-5-oxopyrrolidin-2-yl)-2,5,8,11-tetraazatridecan-13-oic acid
-
- Inchi： 1S/C19H27N5O12/c25-7-11(16(33)20-6-15(31)32)24-19(36)10(5-14(29)30)23-18(35)9(2-4-13(27)28)22-17(34)8-1-3-12(26)21-8/h8-11,25H,1-7H2,(H,20,33)(H,21,26)(H,22,34)(H,23,35)(H,24,36)(H,27,28)(H,29,30)(H,31,32)/t8-,9-,10-,11-/m0/s1
- InChI Key： HJOWVYBCMAYCGY-NAKRPEOUSA-N
- SMILES： O=C([C@@H]1CCC(N1)=O)N[C@H](C(N[C@H](C(N[C@H](C(NCC(=O)O)=O)CO)=O)CC(=O)O)=O)CCC(=O)O
Computed Properties
- Exact Mass: 517.16600
- Monoisotopic Mass: 517.16562131g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 9
- Hydrogen Bond Acceptor Count: 12
- Heavy Atom Count: 36
- Rotatable Bond Count: 15
- Complexity: 907
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 4
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: -4.6
- Topological Polar Surface Area: 278?2
Experimental Properties
- PSA: 277.63000
- LogP: -2.85560
Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI) Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| A2B Chem LLC | AY24239-1mg |
Epidermal Mitosis Inhibiting Pentapeptide |
106678-69-7 | > 95% | 1mg |
$348.00 | 2024-04-20 | |
| A2B Chem LLC | AY24239-5mg |
Epidermal Mitosis Inhibiting Pentapeptide |
106678-69-7 | > 95% | 5mg |
$569.00 | 2024-04-20 | |
| A2B Chem LLC | AY24239-10mg |
Epidermal Mitosis Inhibiting Pentapeptide |
106678-69-7 | > 95% | 10mg |
$752.00 | 2024-04-20 |
Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI) Related Literature
-
Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
-
Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
-
Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
-
Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
-
Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
Additional information on Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI)
Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI) and CAS No. 106678-69-7: A Comprehensive Overview
The compound Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI), identified by the CAS number CAS No. 106678-69-7, represents a significant advancement in the field of peptidomimetics and bioactive peptides. This intricate molecule has garnered considerable attention due to its unique structural features and potential applications in pharmaceutical research and therapeutic development.
Peptides and peptidomimetics have long been recognized for their role in modulating biological processes at the molecular level. Among these, dipeptides and tripeptides with specific sequences exhibit remarkable bioactivity, often mimicking the function of natural peptides while exhibiting improved pharmacokinetic properties. The compound in question, Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI), is a sophisticated example of such a peptidomimetic, designed to interact with biological targets in a highly specific manner.
The structural composition of this compound is characterized by a linear sequence of amino acids, including glycine, 5-oxo-L-prolyl, L-a-glutamyl, L-a-aspartyl, and L-seryl. Each residue contributes to the overall conformation and reactivity of the molecule, making it a versatile tool for studying protein-peptide interactions. The presence of 5-oxo-L-prolyl introduces a kink in the peptide chain, which can influence its binding affinity and specificity. Similarly, the arrangement of L-a-glutamyl and L-a-aspartyl residues enhances its ability to interact with anionic binding sites on target proteins.
Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the binding modes of such compounds with high accuracy. Studies have shown that Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI) can effectively bind to various protein targets, including enzymes and receptors involved in inflammation, pain signaling, and metabolic pathways. This has opened up new avenues for developing novel therapeutic agents that leverage the unique properties of this peptidomimetic.
In particular, the compound has shown promise in preclinical studies as a potential treatment for chronic inflammatory diseases. Its ability to modulate inflammatory pathways without eliciting significant side effects makes it an attractive candidate for further development. Researchers are exploring its potential as an antagonist for inflammatory cytokines and as a modulator of protease activity in chronic wounds.
The synthesis of Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI) presents unique challenges due to its complex structure. Traditional solid-phase peptide synthesis (SPPS) methods have been employed to construct this molecule step-by-step. However, recent innovations in enzymatic synthesis have offered alternative approaches that improve yield and purity while reducing production costs. These advancements are crucial for scaling up production and making such compounds more accessible for clinical trials.
The role of peptidomimetics in drug discovery cannot be overstated. Unlike small-molecule drugs, which often suffer from poor solubility or rapid metabolism, peptides offer greater flexibility in terms of structure and function. The compound CAS No. 106678-69-7 exemplifies this advantage by combining the bioactivity of natural peptides with enhanced stability and bioavailability.
Current research is also exploring the use of this compound in combination therapies. By pairing it with other pharmacological agents, researchers aim to achieve synergistic effects that could lead to more effective treatments for complex diseases. For instance, studies suggest that combining Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI) with anti-inflammatory drugs could provide a more comprehensive approach to managing chronic inflammatory conditions.
The regulatory landscape for peptidomimetics is evolving rapidly as their potential becomes increasingly apparent. Regulatory agencies are developing guidelines to ensure the safety and efficacy of these compounds in clinical use. This includes establishing appropriate dosing regimens, monitoring for adverse effects, and ensuring quality control during manufacturing processes.
Future directions in research on CAS No. 106678-69-7 include exploring its potential applications in other therapeutic areas beyond inflammation management. For example, its ability to interact with specific protein targets suggests it could be useful in treating neurodegenerative diseases or cancer by modulating key signaling pathways involved in these conditions.
The development of novel analytical techniques has also played a crucial role in advancing research on this compound. High-resolution mass spectrometry (HRMS) and nuclear magnetic resonance (NMR) spectroscopy allow researchers to determine the exact structure and purity of peptidomimetics like CAS No. 106678-69-7 with high precision. These techniques are essential for characterizing complex molecules and ensuring their suitability for therapeutic use.
In conclusion, Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI), identified by CAS No. 106678-69-7, represents a significant advancement in peptidomimetic chemistry with broad applications in pharmaceutical research and therapeutic development. Its unique structural features and bioactivity make it a valuable tool for modulating biological processes at the molecular level. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in the development of next-generation therapeutics.
106678-69-7 (Glycine,5-oxo-L-prolyl-L-a-glutamyl-L-a-aspartyl-L-seryl- (9CI)) Related Products
- 25988-63-0(Poly-L-lysine hydrobromide (MW 150000-300000))
- 127103-11-1(Ac-Ser-Asp-Lys-Pro-OH)
- 39537-23-0(L-Alanyl-L-Glutamine)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
